EGFR and lung cancer: Previous findings in EGFR-mutant lung cancers show recurrent aberrations in TP53 (54.6–64.6%), PIK3CA (9−12.4%), CTNNB1 (5.3−9.6%), CDKN2A/B (20.2–24.6%) and CDK4 (7−10%) [18,27,28].